Pascual, Sergi
Feimer, Jan
De Soyza, Anthony
Sauleda Roig, Jaume
Haughney, John
Padullés, Laura
Seoane, Beatriz
Rekeda, Ludmyla
Ribera, Anna
Chrystyn, Henry
Article History
Received: 23 September 2014
Revised: 22 December 2014
Accepted: 3 February 2015
First Online: 30 April 2015
Competing interests
: ADS has received speaker bureau fees, support for attending symposia, for consulting and for organising educational events from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, Forest, GlaxoSmithKline, Novartis and TEVA. He has received institutional grant support for COPD research from AstraZeneca and for bronchiectasis research from Bayer, Forest, Gilead and Novartis. JH has received reimbursements for attending symposia, fees for speaking, for consulting and for organising educational events and funds for research from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Merck Sharp & Dohme, Mundipharma, Novartis and Teva. LP is an employee of Almirall. BS and AR are former employees of Almirall, and current employees of AstraZeneca. LR is an employee of Forest Research Institute, a subsidiary of Actavis PLC. HC has received sponsorship to carry out studies, consultant agreements and honoraria for presentations from Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Innovata Biomed, Meda, Napp Pharmaceuticals, Orion, Teva, Truddell Medical International and UCB. Research sponsorship has also been received from EPSRC and the MRC. The remaining authors declare no conflict of interest.